Last checked at 3 Aug 2020 07:00
Creo Medical Group plc
("Creo" or the "Company")
Video abstract published endorsing Speedboat procedure
Creo Medical Group plc (AIM: CREO), the medical device company, focused on the emerging field of surgical endoscopy, announces that early experience of the Company's Speedboat™ Inject device has shown that it is feasible for performing peroral endoscopic myotomy (POEM) with a good safety profile. The abstract was authored by experts in the field of Gastrointestinal ('GI') therapeutics endoscopy, including Dr. Amit Maydeo an internationally renowned Gastroenterologist and endoscopy expert, known for his pioneering efforts on therapeutic endoscopy.
The main advantages of using Speedboat Inject were highlighted as reducing the risk of injury to the mucosa by the orientation of the hull and use of bipolar radiofrequency, which then aided quick tissue healing and resulted in quicker post-procedural recovery. Speedboat also reduced the overall procedure time, as no device changes were needed for bleeding vessels.
The video abstract, published via an open access content publisher, Thieme Group titled: 'Feasibility of Speedboat RS2 with bipolar radiofrequency energy for peroral endoscopic myotomy in patients with achalasia (with video)' can be viewed online here:
https://www.thieme-connect.com/products/ejournals/html/10.1055/a-1165-0087
Dr Amit Maydeo, Chairman & Chief of Gastroenterology & Therapeutic Endoscopy at the Baldota Institute of Digestive Sciences at the Global hospital in Mumbai, commented: "Our center has been performing POEM for almost a decade and diverticular POEM, and the advent of Speedboat Inject, has certainly opened up new avenues in submucosal endoscopy. We feel the advanced technology of Speedboat overcome many of the problems faced in routine third space procedures. Although the economics of it currently remain unexplored, the device certainly looks to make a huge impact in terms of its advantages over currently existing standard accessories in POEM."
Craig Gulliford, Chief Executive Officer, commented: "We are pleased to see the Speedboat device included in another video abstract as more and more physicians are trained up and performing procedures globally."
Enquires:
Creo Medical Group plc | www.creomedical.com |
Richard Rees (CFO) | +44 (0)1291 606 005 |
|
|
Cenkos Securities plc | +44 (0)20 7397 8900 |
Stephen Keys / Cameron MacRitchie (NOMAD) |
|
Michael Johnson / Russell Kerr (Sales) |
|
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides clinicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by its unique full spectrum kamaptive technology to market, enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. An overview of the Creo Medical device technology portfolio can be seen here:
https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf
For more information about Creo Medical please see our website, www.creomedical.com